Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin-Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis
In brief
Triple oral therapy matched insulin; sensitivity analysis found 3.3 kg less weight
Across 42 trials involving 13,911 adults, triple oral therapy lowered blood sugar about as much as insulin-based treatment, with no clear difference in hypoglycemia over 22 to 36 weeks. A sensitivity analysis found 3.3 kg greater weight reduction with oral therapy, and metformin plus two newer drug classes ranked highest for weight loss; longer-term comparisons remain unknown.
- Journal
- Diabetes/metabolism research and reviews (Q1)
- Published
- 1 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Jie Yu, Chong Rao, Limei Cui, Xinhua Xiao
- PMID
- 43039827
- DOI
- 10.1002/dmrr.70252
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 17 November 2026): Comparative diabetes treatment after dual-therapy failure
Abstract
AIMS: The aim of this systematic review and network meta-analysis was to compare the efficacy and safety of triple oral antidiabetic therapy (3OADs) and insulin-based therapy in patients with type 2 diabetes after dual therapy failure. MATERIALS AND METHODS: Medline (PubMed), Embase, Web of Science, and Cochrane Library were systematically searched (from inception to September 1, 2023). The network meta-analysis included randomized clinical trials (RCTs) of 3OADs and/or insulin-based therapies after dual therapy failure. Mean difference (MD) was extracted for changes in HbA1c and body weight; odds ratio (OR) was extracted for hypoglycemia and adverse events. RESULTS: Forty-two articles (13,911 adult patients) were analysed. 3OADs versus insulin-based therapy showed comparable HbA1c reduction (MD 0.01%; 95% CI, -0.56 to 0.58), weight change (MD -1.59 kg; 95% CI, -3.67 to 0.48), hypoglycemia (OR 0.70; 95% CI, 0.37-1.30), and adverse events (OR 1.68; 95% CI, 1.00-2.82) at 22-36 weeks. Sensitivity analysis revealed that 3OADs significantly reduced weight compared with insulin-based therapy (MD -3.30 kg; 95% CI, -5.56 to -1.05). No significant differences in HbA1c reduction, hypoglycemia incidence, or adverse events were observed between metformin (Met) + dipeptidyl peptidase-4 inhibitor (DPP-4i) + sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and other 3OAD regimens. Meanwhile, Met + DPP-4i + SGLT-2i had the highest probability of achieving the greatest weight reduction. CONCLUSIONS: Compared with insulin-based therapy, 3OADs demonstrated comparable glucose-lowering effects and safety profiles, with a significant weight-sparing benefit observed in sensitivity analysis. Among all 3OAD combinations, Met + DPP-4i + SGLT-2i ranked first for weight loss, without increasing hypoglycemia risk.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.